BACKGROUND: Mucopolysaccharidosis type I is caused by deficiency of α-L-iduronidase. Currently available treatment options include an allogeneic hematopoietic stem cell transplant and enzyme replacement therapy. Exogenous enzyme therapy appears promising but the benefits may be attenuated, at least in some patients, by the development of an immune response to the delivered enzyme. The incidence and impact of alloimmune responses in these patients remain unknown. DESIGN AND METHODS: We developed an immunoglobulin G enzyme-linked immunosorbent assay as well as in vitro catalytic enzyme inhibition and cellular uptake inhibition assays and quantified enzyme inhibition by allo-antibodies. We determined the impact of these antibodies in eight patients who received enzyme therapy before and during hematopoietic stem cell transplantation. In addition, 20 patients who had previously received an allogeneic stem cell transplant were tested to evaluate this treatment as an immune tolerance induction mechanism. RESULTS: High titer immune responses were seen in 87.5% (7/8) patients following exposure to α-L-iduronidase. These patients exhibited catalytic enzyme inhibition (5/8), uptake inhibition of catalytically active enzyme (6/8) or both (4/8). High antibody titers generally preceded elevation of previously described biomarkers of disease progression. The median time to development of immune tolerance was 101 days (range, 26-137) after transplantation. All 20 patients, including those with mixed chimerism (22%), tested 1 year after transplantation were tolerized despite normal enzyme levels. CONCLUSIONS: We found a high incidence of neutralizing antibodies in patients with mucopolysaccharidosis type I treated with enzyme replacement therapy. We also found that allogeneic hematopoietic stem cell transplantation was an effective and rapid immune tolerance induction strategy.
BACKGROUND:Mucopolysaccharidosis type I is caused by deficiency of α-L-iduronidase. Currently available treatment options include an allogeneic hematopoietic stem cell transplant and enzyme replacement therapy. Exogenous enzyme therapy appears promising but the benefits may be attenuated, at least in some patients, by the development of an immune response to the delivered enzyme. The incidence and impact of alloimmune responses in these patients remain unknown. DESIGN AND METHODS: We developed an immunoglobulin G enzyme-linked immunosorbent assay as well as in vitro catalytic enzyme inhibition and cellular uptake inhibition assays and quantified enzyme inhibition by allo-antibodies. We determined the impact of these antibodies in eight patients who received enzyme therapy before and during hematopoietic stem cell transplantation. In addition, 20 patients who had previously received an allogeneic stem cell transplant were tested to evaluate this treatment as an immune tolerance induction mechanism. RESULTS: High titer immune responses were seen in 87.5% (7/8) patients following exposure to α-L-iduronidase. These patients exhibited catalytic enzyme inhibition (5/8), uptake inhibition of catalytically active enzyme (6/8) or both (4/8). High antibody titers generally preceded elevation of previously described biomarkers of disease progression. The median time to development of immune tolerance was 101 days (range, 26-137) after transplantation. All 20 patients, including those with mixed chimerism (22%), tested 1 year after transplantation were tolerized despite normal enzyme levels. CONCLUSIONS: We found a high incidence of neutralizing antibodies in patients with mucopolysaccharidosis type I treated with enzyme replacement therapy. We also found that allogeneic hematopoietic stem cell transplantation was an effective and rapid immune tolerance induction strategy.
Authors: Juna M de Vries; Nadine A M E van der Beek; Marian A Kroos; Lale Ozkan; Pieter A van Doorn; Susan M Richards; Crystal C C Sung; Jan-Dietert C Brugma; Adrienne A M Zandbergen; Ans T van der Ploeg; Arnold J J Reuser Journal: Mol Genet Metab Date: 2010-08-14 Impact factor: 4.797
Authors: Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen Journal: Mol Genet Metab Date: 2010-01 Impact factor: 4.797
Authors: Robert F Wynn; J Ed Wraith; Jean Mercer; Anne O'Meara; Karen Tylee; Margaret Thornley; Heather J Church; Brian W Bigger Journal: J Pediatr Date: 2009-04 Impact factor: 4.406
Authors: Kia Jane Langford-Smith; Jean Mercer; June Petty; Karen Tylee; Heather Church; Jane Roberts; Gill Moss; Simon Jones; Rob Wynn; J Ed Wraith; Brian W Bigger Journal: J Inherit Metab Dis Date: 2010-12-18 Impact factor: 4.982
Authors: Minke H de Ru; Linda van der Tol; Naomi van Vlies; Brian W Bigger; Carla E M Hollak; Lodewijk Ijlst; Wim Kulik; Henk van Lenthe; Muhammad A Saif; Tom Wagemans; Willem M van der Wal; Ronald J Wanders; Frits A Wijburg Journal: J Inherit Metab Dis Date: 2012-09-19 Impact factor: 4.982
Authors: Daniel H Wiseman; Jean Mercer; Karen Tylee; Nilima Malaiya; Denise K Bonney; Simon A Jones; J Edmond Wraith; Robert F Wynn Journal: J Inherit Metab Dis Date: 2012-06-21 Impact factor: 4.982
Authors: Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger Journal: Mol Ther Date: 2012-05-01 Impact factor: 11.454
Authors: Arunabha Ghosh; Weston Miller; Paul J Orchard; Simon A Jones; Jean Mercer; Heather J Church; Karen Tylee; Troy Lund; Brian W Bigger; Jakub Tolar; Robert F Wynn Journal: Mol Genet Metab Date: 2016-01-27 Impact factor: 4.797
Authors: Abhijit Ricky Pal; Eveline J Langereis; Muhammad A Saif; Jean Mercer; Heather J Church; Karen L Tylee; Robert F Wynn; Frits A Wijburg; Simon A Jones; Iain A Bruce; Brian W Bigger Journal: Orphanet J Rare Dis Date: 2015-04-10 Impact factor: 4.123
Authors: Ana Sergijenko; Alexander Langford-Smith; Ai Y Liao; Claire E Pickford; John McDermott; Gabriel Nowinski; Kia J Langford-Smith; Catherine L R Merry; Simon A Jones; J Edmond Wraith; Robert F Wynn; Fiona L Wilkinson; Brian W Bigger Journal: Mol Ther Date: 2013-06-07 Impact factor: 11.454